NORCROSS, GA -- (Marketwired) -- 03/13/14 -- RayBiotech, Inc. ("RBI") announced today that it has executed a master services and supply agreement with the therapeutic stem cell company California Stem Cell, Inc. (CSC). CSC utilizes high-purity stem cells in a number of therapeutics applications including for the treatment of melanoma, ovarian cancer and a variety of neurologic disorders. Under the terms of this agreement, California Stem Cell will receive preferred pricing and other proprietary guarantees on both services and products from RayBiotech. The financial terms were not disclosed.
Dr. Alexa Poole, Senior Scientist at California Stem Cell, said, "As we optimize and test our stem cell-based therapeutic platforms, RayBiotech's biomarker analysis services, products and technologies have enabled us to streamline our biochemical data analysis strategy, providing broad coverage of biomarker assessment in a variety of applications and scenarios."
Commenting on the agreement, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, "California Stem Cell is at the forefront of the stem cell therapeutics industry. We applaud their efforts to develop stem cell-based therapeutics and are pleased that RayBiotech's antibody array and ELISA biomarker characterization technologies suit the needs of researchers and scientists at CSC. We also congratulate California Stem Cell on their recent FDA approval to enter Phase III clinical trials for stem cell-based treatment of metastatic melanoma. It is with great satisfaction that we are able to provide CSC with biomarker characterization technologies for this and other therapeutic endeavors."
About RayBiotech, Inc.
In 2001, RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485: 2003 certification and are featured in thousands of publications, including: Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).
About California Stem Cell, Inc.
California Stem Cell Inc. (CSC) is an Irvine, CA-based company focused on the development of stem cell-based therapies for metastatic cancers and neuromuscular disorders such as spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).
CSC has proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and cGMP processes.